Amgen's BLA761298 for PAVBLU Receives AP Status from FDA
The FDA has granted application BLA761298 for PAVBLU an Approval Pending (AP) status.
Asset / Drug
Drug and asset intelligence for BLA761298 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
VEGF Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.